| Literature DB >> 34250276 |
Hideki Arai1,2, Masafumi Nozoe3, Satoru Matsumoto1, Takeshi Morimoto2.
Abstract
Background: Exercise loading is contraindicated for patients with severe aortic stenosis (AS); however, everyday activities mandate the inclusion of a light load. The aim of this study was to investigate the efficacy and safety of exercise training for patients with severe AS who were admitted to a rehabilitation ward because of physical disability. Methods andEntities:
Keywords: Disuse syndrome; Motor disorder; Neurological disease; Rehabilitation; Severe aortic stenosis
Year: 2021 PMID: 34250276 PMCID: PMC8258178 DOI: 10.1253/circrep.CR-21-0035
Source DB: PubMed Journal: Circ Rep ISSN: 2434-0790
Exercise Training Program
| Intensity and strength | Duration of 1 session | Frequency | |
|---|---|---|---|
| Aerobic exercise | 5–10 min | 1–3 sessions/day | |
| RPE (Borg scale): 10–11 | 7 days/week | ||
| Resistance training | 10–20% of 1RM | – | 5–10 repetitions/set |
| RPE (Borg scale): 10–11 | 1–3 sets/day | ||
| 7 days/week |
The percentage of 1 repetition maximum (1RM) was calculated from actual measured values in individuals. K, Karvonen value; RPE, ratings of perceived exertion.
Figure 1.Flow diagram.
Characteristics of Patients With Disability and Severe Aortic Stenosis
| Patient | Age | Sex | Target disease for | NYHA | EuroSCORE | CTR | AVA | AV-Vel | LVEF | NT-proBNP |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 93 | Female | Femoral neck fracture | I | 7.4 | 47.6 | 0.9 | 3.2 | 40.0 | 3,872 |
| 2 | 94 | Female | Femoral neck fracture | I | 5.6 | 50.8 | 0.5 | 4.3 | 65.6 | 1,386 |
| 3 | 93 | Female | Femoral neck fracture | II | 16.5 | 76.0 | 0.4 | 4.5 | 59.0 | 9,430 |
| 4 | 88 | Male | Femoral trochanteric | I | 2.3 | 50.0 | 0.4 | NA | 61.0 | 739 |
| 5 | 91 | Female | Femoral trochanteric | I | 2.6 | 70.4 | NA | 3.8 | 70.0 | 626 |
| 6 | 76 | Female | Femoral trochanteric | I | 2.0 | 61.1 | 0.3 | 5.6 | 68.0 | 9,149 |
| 7 | 83 | Female | Periprosthetic fracture | I | 9.8 | 46.9 | 0.4 | 3.8 | 66.2 | 431 |
| 8 | 84 | Female | Hip osteoarthritis | I | 2.5 | 53.3 | 0.6 | 3.7 | 85.0 | 87 |
| 9 | 87 | Female | Cerebral infarction | I | 4.7 | 72.5 | NA | 4.1 | 51.0 | 4,020 |
| 10 | 82 | Male | Cerebral infarction | II | 3.7 | 62.9 | NA | 4.0 | 84.0 | 7,517 |
| 11 | 84 | Female | Cervical spondylotic | I | 2.5 | 53.1 | 0.6 | 3.7 | 72.0 | 46 |
| 12 | 86 | Female | Disuse syndrome | I | 4.3 | 46.0 | 0.2 | 4.1 | 73.1 | 265 |
| 13 | 86 | Female | Disuse syndrome | I | 3.6 | 57.2 | 0.7 | 3.2 | 74.7 | 656 |
| 14 | 87 | Male | Disuse syndrome | I | 6.0 | 74.9 | 0.6 | 4.0 | 38.6 | 7,555 |
| 15 | 95 | Female | Disuse syndrome | II | 6.4 | 49.6 | 0.3 | 4.0 | 68.0 | 5,160 |
| 16 | 87 | Female | Disuse syndrome | II | 4.9 | 59.4 | 0.3 | 4.7 | 77.6 | 1,376 |
| 17 | 84 | Male | Disuse syndrome | III | 11.0 | 67.8 | 0.4 | 3.4 | 13.0 | 23,954 |
| 18 | 94 | Female | Disuse syndrome | III | 7.4 | 63.9 | 1.0 | 4.1 | 55.0 | 3,166 |
AV-Vel, peak aortic jet velocity; AVA, aortic valve area; CTR, cardiothoracic ratio; EuroSCORE II, European System for Cardiac Operative Risk Evaluation; LVEF, left ventricular ejection fraction; NA, not assessed; NT-proBNP, N-terminal pro B-type natriuretic peptide; NYHA, New York Heart Association.
Diagnosis of Severe AS, Treatments for Severe AS, Past History, Comorbidities, Medications, and Laboratory Data of Patients With Severe AS (n=18)
| 14 (78) | |
| Balloon aortic valvuloplasty | 1 (6) |
| Conservative therapy | 13 (72) |
| Heart failure | 4 (22) |
| Coronary artery disease | 3 (17) |
| Cerebrovascular disease | 2 (11) |
| Valvular heart disease other than AS | 13 (72) |
| Atrial fibrillation | 6 (33) |
| Hypertension | 11 (61) |
| Diabetes | 6 (33) |
| Hyperlipidemia | 1 (6) |
| Anemia | 12 (67) |
| Chronic kidney disease | 3 (17) |
| Chronic liver disease | 5 (28) |
| Motor function disorder | 5 (28) |
| Hypothyroidism | 3 (17) |
| Cervical spondylotic myelopathy | 1 (6) |
| Dementia | 11 (61) |
| Angiotensin-converting enzyme inhibitor | 3 (17) |
| Angiotensin II receptor blocker | 3 (17) |
| β-blocker | 3 (17) |
| Spironolactone | 6 (33) |
| Furosemide | 2 (11) |
| Tolvaptan | 3 (17) |
| Digoxin | 1 (6) |
| Aspirin | 2 (11) |
| Clopidogrel | 2 (11) |
| Apixaban | 2 (11) |
| Rivaroxaban | 2 (11) |
| Edoxaban | 1 (6) |
| Hemoglobin (g/dL) | 10.6 [8.0–13.5] |
| Creatinine (mg/dL) | 0.8 [0.4–1.4] |
| Blood urea nitrogen (mg/dL) | 18.1 [9.4–45.4] |
| Serum protein (g/dL) | 6.3 [5.3–7.9] |
| Serum albumin (g/dL) | 3.6 [2.2–4.0] |
Data are presented as the median [range] or n (%). AS, aortic stenosis.
Clinical Outcome of Patients With Severe Aortic Stenosis
| Patient no. | Clinical outcome |
|---|---|
| 1 | Discharge to a long-term care facility |
| 2 | Discharge home |
| 3 | Discharge home |
| 4 | Discharge home |
| 5 | Discharge home |
| 6 | Discharge to a long-term care facility |
| 7 | Discharge home |
| 8 | Discharge home |
| 9 | Transfer to another hospital due to stroke |
| 10 | Transfer to another hospital due to anemia |
| 11 | Discharge home |
| 12 | Discharge home |
| 13 | Died due to pneumonia |
| 14 | Died due to pneumonia |
| 15 | Discharge to a long-term care facility |
| 16 | Discharge home |
| 17 | Died due to heart failure |
| 18 | Transfer to another hospital due to heart failure |
Figure 2.Comparison of time courses of Functional Independence Measure (FIM) scores from admission to discharge in the 12 patients who completed convalescent rehabilitation.